Results of a recently completed study found that an experimental cannabinoid-based topical medicine achieved an extraordinary 90% success rate in healing chronic wounds. /PRNewswire/ — Using technology adapted from NASA’s Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating… Your access to this site has been limited by the site owner If you think you have been blocked in error, contact the owner of this site for assistance. If you are a WordPress user with
Cannabis-Based Medicine: A Breakthrough For Healing Intractable Chronic Wounds
Chronic wounds disproportionately affect older adults, severely impairing their health and quality of life. Aging diminishes our capacity for healing, and conditions such as diabetes, vascular disease, cancer and surgical procedures put elder adults at further risk of developing chronic wounds.
While notoriously difficult to heal, a new, experimental cannabinoid-based treatment promises to vastly improve the prognosis for the millions of older adults who suffer from chronic wounds.
A Multi-Billion Dollar Market
According to the American Professional Wound Care Association, non-healing wounds impact some 15% of Medicare beneficiaries, and the costs associated with treating them can reach $30 Billion.
The anti-inflammatory properties of cannabinoids are driving investigations into potential therapies for an entire spectrum of disease states, and treatment for chronic wound healing is one of them.
Results of a recently completed study found that an experimental cannabinoid-based topical medicine achieved an extraordinary 90% success rate in healing chronic wounds. Dr. Vincent Maida, a palliative medicine specialist at the University of Toronto and principal investigator of the study, recruited thirty patients in an open-label study testing his proprietary Topical Cannabis-Based Medicines (TCBM). Twenty-seven of the participants achieved complete closure of wounds that, in some cases, had resisted healing for over a decade.
Cannabinoids for healing
Dr. Maida has been investigating cannabinoids for treating pain and wounds for over 20 years. During a graduate program on wounds at University of Toronto’s Dalla Lana School of Public Health, he encountered a pre-clinical study showing evidence of the efficacy of cannabinoids for wound healing. He recalls: “My supervisor thought I was off my rocker that I thought that cannabinoids could be effective for treating integumentary (the skin and mucous membrane system) and wound conditions. Since then the basic science has been catching up and validating all of my research.”
The Making Of New York’s $150 Million ‘Cannabis Campus’
Blackstone To Sell The Cosmopolitan Of Las Vegas For $5.65 Billion
The Feds Are Coming For Delta-8 THC
He recalls: “When I started recommending cannabinoid therapies to my patients, I was considered a heretic.” But when Canada broadened the definition of medical cannabis to include extracts as well as dried botanical flower, Dr. Maida developed and patented his own formulations, and started to recruit patients for his study. He now holds what he claims to be the world’s first patents on Topical Cannabis-Based Medicines (TCBM) indicated for Integumentary and Wound Management.
The worst of the worst
Dr. Maida runs a tertiary wound clinic in the Toronto area, where he receives referrals of the most severe wounds in southern Ontario. As he explains, “Everyone else’s failures come to me. I get the worst of the worst.”
Through his recent study, he was able to subject some of those recalcitrant wounds to his innovations and intellectual property. And according to Dr. Maida, “I’m having results that are just absolutely mind-blowing.”
“I’m actually the first on record worldwide to start applying cannabis products to wounds to help with pain management, and now showing that it can heal the unhealable wounds in very elderly and sick patients. I’m literally healing wounds that otherwise people would be dying from or dying with… When I show the before and after pictures, people can’t believe that these results are real – but they are real!”
“So if I’m able to heal the worst of the worst, imagine what my innovations can do for everyday burns and scrapes and so forth.”
Anti-inflammatory, lipophilic agents
Chronic inflammation is at the heart of a non-healing wound. Normally a wound progresses through an orderly cascade of phases from the time of initial trauma until it is fully healed. As Dr. Maida explains, wounds that don’t heal get stuck in the inflammatory stage. “There’s ample pre-clinical information already published that THC and CBD and other elements of cannabis extracts have anti-inflammatory properties. My cannabinoid-based medicines are rebooting the wound out of that chronic inflammatory stage.”
“The other thing that made me realize that wounds and cannabis were going to mix is that intact skin is hydrophilic, but a wound, on the other hand, is lipophilic. That kind of tissue can absorb THC and CBD which are also lipophilic. So it’s a perfect fit. This was one of my epiphany moments: that the very molecules that are anti-inflammatory in the cannabis extract are going to be able to be absorbed rapidly into a wound bed.”
“So everything is lining up. The endocannabinoid system (ECS) is present in the integumentary system which is the largest organ of the body. And there’s a huge opportunity to activate the ECS through the integument, and promote things like healing wounds and relieving pain from wounds – because when you heal a wound, the pain goes away.”
A partner for the next stage
At this point, Dr. Maida is looking for a partner to help take his proprietary IP to the next level, and get his products on the market to help millions of people.
According to Dr. Maida, much of the money and effort spent on treating chronic wound is in vain. “One of the areas with the worst outcomes is wounds – in terms of pain relief and healing, the results are dismal. We’re spending billions and spinning our wheels.”
Until now, Dr. Maida has self-funded the R&D of his proprietary therapies. And he believes that, seeing patients with chronic wounds week in and week out, with no prospect of improvement, was what drove him to make the personal and financial sacrifice, to give his patients hope.
The follow-up randomized controlled study is already designed and waiting. At this point, all he needs is a partner with the resources to help launch it. “It’s really what’s driving me – at a time when my colleagues are retiring, I am working on probably the greatest project in my entire career.”
Hospitals Succeed in Eliminating Deadly Bedsores
MANCHESTER, England and LOS ANGELES , Dec. 23, 2016 /PRNewswire/ — Using technology adapted from NASA’s Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
Nurses dramatically cut bedsore occurrence by detecting damage developing under patients’ skin early enough to intervene and reverse the damage. This marks a breakthrough in prevention of the chronic condition costing the UK £2.1bn annually, which claimed the life of Superman actor Christopher Reeve .
Bruin Biometrics (“BBI LLC”), which manufactures the early detection technology known as the SEM Scanner, enlisted 13 hospitals (including 10 NHS England Trusts) to participate in a novel Pressure Ulcer Prevention Program (PURP) incorporating SEM Scanner into existing care pathways for pressure ulcer prevention.
The findings from over 1200 patients scanned are the most comprehensive real-world evidence that this early detection technology enables nurses to prevent bedsores before they break through the skin, a conclusion that upends the prevailing view that bedsores cannot be diagnosed and treated until they have caused visible and irreversible damage to the skin’s surface.
“These data challenge existing practice that looks for visual changes to skin to initiate bedsore intervention,” BBI CEO Martin Burns said. “Scientific findings show that by the time damage is visible, it is far too late. Early detection changed the prognosis for millions of cancer survivors. A proactive approach to ‘Act Before Red’ is consistently doing the same for bedsores, on a large scale, across independent sites.”
“We reduced pressure ulcers in the ward concerned to zero during our Scanner trial – an achievement that, if we rolled out across our hospital, we estimate could save our hospital nearly £600,000 and release 1,420 hours of nurse productivity annually,” said Glenn Smith , a tissue viability and nutrition senior clinical nurse specialist/patient safety lead at St. Mary’s Hospital, part of the NHS Trust on the Isle of Wight, which has a large elderly population at risk for bedsores due to immobility.
“In our pilot program, which included over 200 patients, we reduced bedsore incidence by 90%,” said Rose Raizman , nurse practitioner, enterostomal therapist and pressure ulcer prevention at Scarborough and Rouge Hospital in Ontario, Canada . “SEM Scanner allows the clinician to ‘visualise pathology’ below the skin level before it becomes apparent at the surface, and should be used as the standard of care for pressure ulcer prevention.”
“The vast majority of nurses participating in our Scanner program said the device provided valuable clinical information,” added Parker Moss , chief technology and transformation officer at Virgin Care, which experienced a 95 percent drop in the bedsore rate during an evaluation of the device at Farnham Community Hospital in Surrey , where it provides services to the NHS.
SEM Scanner is a wireless non-invasive handheld device that assesses sub-epidermal moisture, or SEM, an indicator of early-stage damage beneath the skin surface as much as 10 days earlier than visual inspection by nurses.
SEM Scanner was conceived by Barbara Bates-Jensen , a wound care expert and professor at the University of California at Los Angeles ( UCLA ), and adapted from seismology technology used on NASA’s Mars landing craft to interrogate beneath the planet’s surface. Professor Bates-Jensen, Dr. Majid Sarrafzadeh , and Dr. William J. Kaiser , co-director of the UCLA Wireless Health Institute and a former engineer at Jet Propulsion Laboratories, partnered with BBI to adapt the space technology into the SEM Scanner.
Bedsores, also known as pressure ulcers, are chronic wounds to the skin and tissue that often develop in patients who are immobile.
Bedsores commonly lead to infection and death. In fact, bedsores kill more people annually than any form of cancer except lung cancer. There are nearly 500,000 bedsore cases annually in the UK.
Until now, diagnosis has relied on visual inspection by nurses, which is subjective and which can only identify bedsores once visible damage to the skin has already begun. With early-detection, experts believe that over 80% of early-stage pressure ulcers can be prevented.
“We’ve borrowed NASA’s concept of ‘Seeing the Unseen’ to develop the first clinically-proven method for detecting unseen bedsores and alerting healthcare practitioners in real time when they begin to form under the skin,” said Rachael Lester , BBI VP of Product. “With early detection, clinicians can initiate treatment before chronic damage develops. More and more clinicians are using the SEM Scanner and finding that they can overcome avoidable PUs, proving that ZERO is no longer Mission: Impossible.”
Real-world evaluation data presented by St. Mary’s Hospital (Improved Patient Safety with Use of the SEM Scanner) and Virgin Care (Chasing Zero. Results from a New Pressure Ulcer Prevention Bundle) at the Wounds UK annual conference November 14-16 in Harrogate and are now being released publicly for the first time.
Bedsores, also known as pressure ulcers, are a common medical problem that can lead to pain, disfigurement, infection and death. Pressure ulcers are an area of localized damage to the skin and underlying tissue – usually around an area of bony prominence, such as the sacrum, coccyx, heels, and hips – that results from pressure involving shear and/or friction. Across Europe and the United States , it is estimated that 18%-25% of patients in both acute care and long-term care settings suffer from pressure ulcers, disproportionately impacting the elderly and patients with limited mobility. There are some 2.5 million pressure ulcer cases annually in the European Union, and nearly 500,000 in the United Kingdom , which spends £2.1bn, or 4% of the NHS budget, on the condition. In the U.S., some 2.5 million Americans develop pressure ulcers annually in acute care facilities, and 60,000 Americans die annually from pressure ulcer complications such as cancer, sepsis, cellulitis, and MRSA.
Bruin Biometrics LLC, a pioneer in biometric-sensor based medical devices, is committed to the development of point-of-care diagnostic solutions for early detection and monitoring of chronic, preventable conditions. The company’s first product is the SEM Scanner, a hand-held non-invasive device that assesses sub-epidermal moisture, a biomarker which has been found to detect early-stage pressure ulcers as much as 10 days earlier than visual observation. Pressure ulcers affect approximately 25% of acute care hospital and long-term care patients – typically the elderly and immobile. SEM Scanner is CE Mark approved and is currently in full commercial launch in the EU and Canada . SEM Scanner is not currently for sale in the United States .
BBI is also developing OrthoSonos, a non-invasive device for real-time orthopaedic joint monitoring and assessment of prosthetic implant failure; and P02M, the first device for monitoring tissue oxygenation at a specific location in real time. P02M is initially being tested for continual monitoring of tissue and vascular viability in the feet of diabetics. Diabetes can cause peripheral artery disease and peripheral neuropathy, putting patients at risk for foot ulcers.
BBI is based in Los Angeles and maintains a European office in Manchester, UK .
Your access to this site has been limited by the site owner
If you think you have been blocked in error, contact the owner of this site for assistance.
If you are a WordPress user with administrative privileges on this site please enter your email in the box below and click “Send”. You will then receive an email that helps you regain access.
Block Technical Data
|Block Reason:||Access from your area has been temporarily limited for security reasons|
|Time:||Sat, 20 Aug 2022 13:22:37 GMT|